Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: Reducing extrapyramidal symptoms

CNS Spectrums

Volumn 18, Issue 6, 2013, Pages 285-288

  Stahl, Stephen M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA 1 ADRENERGIC RECEPTOR; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE; GLUTAMIC ACID; ILOPERIDONE; NEUROLEPTIC AGENT; NORADRENALIN; QUETIAPINE; SEROTONIN; SEROTONIN 2A RECEPTOR;

AKATHISIA; ALPHA ADRENERGIC RECEPTOR BLOCKING; CORPUS STRIATUM; DOPAMINE RELEASE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NIGRONEOSTRIATAL SYSTEM; PARKINSONISM; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RECEPTOR OCCUPANCY; REVIEW;

EID: 84890033510     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852913000850     Document Type: Review

References (15)

1. Stahl SM. Stahl's Essential Psychopharmacology, 4th ed. Cambridge, UK: Cambridge University Press; 2013.
2. Mitzenberg MJ, Yoon JH. An index of relative central a-adrenergic receptor antagonism by antipsychotic medications. Exp Clin Psychopharmacol. 2011; 19: 31-39.
3. Tarazi F, Stahl SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012; 13(13): 1911-1922.
4. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008; 23(2 Suppl 1): S12-19.
5. Cutler AJ, Kalali AH, Mattingly GW, Kunovac J, Meng X. Long-term safety and tolerability of iloperidone: results from a 25 week, open-label extension trial. CNS Spectr. 2013; 18(1): 43-54.
6. National Institutes of Mental Health. Psychoactive Drug Screening Program. 2012. Available from: http://pdsp.med.unc.edu/indexR.html.
7. Marek GJ, Aghahanian GK. 5HT2A receptor or alpha 1 adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol. 1999; 367: 197-206.
8. Marek GJ, Aghajanian GK. Alpha 1B-adrenoceptormedicated excitation of piriform cortical interneurons. Eur J Pharmacol. 1996; 305: 95-100.
9. Pudovkina OL, Cremers T, Westerink B. Regulation of the release of serotonin in the dorsal raphe nucleus by alpha 1 and alpha 2 adrenoceptors. Synapse. 2003; 50: 77-82.
10. Amargós-Bosch M, Adell A, Bortolozzi A, Artigas F. Stimulation of alpha 1 adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs. J Neurochem. 2003; 87(4): 831-842.
11. Mitrano D, Schroeder JP, Smith Y, et al. a-1 adrenergic receptors are localized on presynaptic elements in the nucleus accumbens and regulate mesolimbic dopamine transmission. Neuropsychopharmacology. 2012; 37(9): 2161-2172.
12. Coteccia S. The a1-adrenergic receptors: diversity of signaling networks and regulation. J Recept Signal Transduct Res. 2010; 30: 410-419.
13. Pudovkina OL, Westerink B. Functional role of alpha 1 adrenoceptors in the locus coeruleus: a microdialysis study. Brain Res. 2005; 1061: 50-56.
14. Drouin C, Blanc G, Trovero F, Glowinski J, Tassin J-P. Cortical alpha 1 adrenergic regulation of acute and sensitized morphine locomotor effects. Neuroreport. 2001; 12: 3483-3486.
15. Svensson TH. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27: 1145-1158.